Company Overview
About SFA Therapeutics
SFA Therapeutics is a Philadelphia-based clinical-stage biotech developing oral small molecule drugs that modulate regulatory T cells (Tregs) — the immune system's natural suppressor cells — to restore immune homeostasis in autoimmune diseases and cancer without the broad immunosuppression that existing biologics and small molecule therapies cause. The company raised $9.13 million from investors including Savantus Ventures and Ben Franklin Technology Partners, announced positive Phase 1b safety data for SFA-002 in psoriasis in March 2025, and received a 2025 Prix Galien USA Best Startup award nomination.
Business Model & Competitive Advantage
SFA Therapeutics' Treg modulator approach targets a fundamentally different mechanism than approved autoimmune drugs: rather than blocking specific inflammatory cytokines (like TNF inhibitors) or broadly depleting immune cells (like many chemotherapy agents), SFA-002 and related compounds selectively increase the activity or number of Tregs — the cells that naturally regulate immune responses and prevent autoimmunity. This "restore natural balance" mechanism could potentially treat autoimmune diseases while preserving normal immune function more completely than current approaches.
Competitive Landscape 2025–2026
In 2025, SFA competes in the autoimmune drug discovery and Treg biology space with Sonoma Biotherapeutics, Quell Therapeutics (Treg cell therapy), Cue Biopharma (Treg-stimulating biologics), and the established small molecule immunology companies (AbbVie with Humira/Skyrizi, Pfizer with Xeljanz) for autoimmune disease treatment. The Treg biology field has generated significant scientific interest — if oral small molecules can selectively activate Tregs without causing immunosuppression or infection risk, the therapeutic window for autoimmune diseases could be dramatically expanded. Psoriasis Phase 1b safety data is the first human clinical validation of the approach. The 2025 strategy focuses on advancing SFA-002 through Phase 2 proof-of-concept trials in psoriasis, exploring additional autoimmune indications (rheumatoid arthritis, inflammatory bowel disease), and building the chemistry platform for next-generation Treg modulators.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
SFA Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Compare SFA Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from SFA Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim SFA Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention SFA Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →